|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tian JDC and Liang L: Involvement of
circular RNA SMARCA5/microRNA-620 axis in the regulation of
cervical cancer cell proliferation, invasion and migration. Eur Rev
Med Pharmacol Sci. 22:8589–8598. 2018.PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Salvatici M, Achilarre MT, Sandri MT,
Boveri S, Vanna Z and Landoni F: Squamous cell carcinoma antigen
(SCC-Ag) during follow-up of cervical cancer patients: Role in the
early diagnosis of recurrence. Gynecol Oncol. 142:115–119. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Solans L, Gonzalo-Asensio J, Sala C,
Benjak A, Uplekar S, Rougemont J, Guilhot C, Malaga W, Martín C and
Cole ST: The PhoP-dependent ncRNA Mcr7 modulates the TAT secretion
system in Mycobacterium tuberculosis. PLoS Pathog. 10:e10041832014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schwartz S, Bernstein DA, Mumbach MR,
Jovanovic M, Herbst RH, León-Ricardo BX, Engreitz JM, Guttman M,
Satija R, Lander ES, et al: Transcriptome-wide mapping reveals
widespread dynamic-regulated pseudouridylation of ncRNA and mRNA.
Cell. 159:148–162. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lei B, Xu SP, Liang XS, Li YW, Zhang JF,
Zhang GQ and Pang D: Long non-coding RNA MVIH is associated with
poor prognosis and malignant biological behavior in breast cancer.
Tumour Biol. 37:5257–5264. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jalali S, Bhartiya D, Lalwani MK,
Sivasubbu S and Scaria V: Systematic transcriptome wide analysis of
lncRNA-miRNA interactions. PLoS One. 8:e538232013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chi S, Shen L, Hua T, Liu S, Zhuang G,
Wang X, Zhou X, Wang G and Wang H: Prognostic and diagnostic
significance of lncRNAs expression in cervical cancer: A systematic
review and meta-analysis. Oncotarget. 8:79061–79072. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang JP, Yang XJ, Xiao L and Wang Y: Long
noncoding RNA PVT1 as a novel serum biomarker for detection of
cervical cancer. Eur Rev Med Pharmacol Sci. 20:3980–3986.
2016.PubMed/NCBI
|
|
11
|
Liao LM, Sun XY, Liu AW, Wu JB, Cheng XL,
Lin JX, Zheng M and Huang L: Low expression of long noncoding
XLOC_010588 indicates a poor prognosis and promotes proliferation
through upregulation of c-Myc in cervical cancer. Gynecol Oncol.
133:616–623. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hidai H, Bardales R, Goodwin R,
Quertermous T and Quertermous EE: Cloning of capsulin, a basic
helix-loop-helix factor expressed in progenitor cells of the
pericardium and the coronary arteries. Mech Dev. 73:33–43. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu J, Richardson JA and Olson EN:
Capsulin: A novel bHLH transcription factor expressed in epicardial
progenitors and mesenchyme of visceral organs. Mech Dev. 73:23–32.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Quaggin SE, Vanden Heuvel GB and Igarashi
P: Pod-1, a mesoderm-specific basic-helix-loop-helix protein
expressed in mesenchymal and glomerular epithelial cells in the
developing kidney. Mech Dev. 71:37–48. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Plotkin M and Mudunuri V: Pod1 induces
myofibroblast differentiation in mesenchymal progenitor cells from
mouse kidney. J Cell Biochem. 103:675–690. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Quaggin SE, Schwartz L, Cui S, Igarashi P,
Deimling J, Post M and Rossant J: The basic-helix-loop-helix
protein pod1 is critically important for kidney and lung
organogenesis. Development. 126:5771–5783. 1999.PubMed/NCBI
|
|
17
|
Cui S, Schwartz L and Quaggin SE: Pod1 is
required in stromal cells for glomerulogenesis. Dev Dyn.
226:512–522. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Katagiri A, Nakayama K, Rahman MT, Rahman
M, Katagiri H, Nakayama N, Ishikawa M, Ishibashi T, Iida K,
Kobayashi H, et al: Loss of ARID1A expression is related to shorter
progression-free survival and chemoresistance in ovarian clear cell
carcinoma. Mod Pathol. 25:282–288. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y,
Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, et
al: ARID1A mutations in endometriosis-associated ovarian
carcinomas. N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bitler BG, Aird KM, Garipov A, Li H,
Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih IeM,
Conejo-Garcia JR, et al: Synthetic lethality by targeting EZH2
methyltransferase activity in ARID1A-mutated cancers. Nat Med.
21:231–238. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dykhuizen EC, Hargreaves DC, Miller EL,
Cui K, Korshunov A, Kool M, Pfister S, Cho YJ, Zhao K and Crabtree
GR: BAF complexes facilitate decatenation of DNA by topoisomerase
IIα. Nature. 497:624–627. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mathur R, Alver BH, San Roman AK, Wilson
BG, Wang X, Agoston AT, Park PJ, Shivdasani RA and Roberts CW:
ARID1A loss impairs enhancer-mediated gene regulation and drives
colon cancer in mice. Nat Genet. 49:296–302. 2017. View Article : Google Scholar : PubMed/NCBI
|
